Skip to main content

Table 1 Univariate analysis for the association of various clinicopathologica features with SAA expressions of patients with ovarian cancer

From: Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Feature N.(n = 100) SAA [mg/L, M (QR)] Z P
Age(y)
  ≥ 60 55 (55%) 51.7 (15.63,187.95) 1.254 0.516
  < 60 45 (45%) 57.6 (18.35,180.7)   
FIGO stage
 I-II 30 (30%) 8.8 (6.30,32. 3) 7.106 0.003
 III 25 (25%) 42.1 (12.8166.35)   
 IV 45 (45%) 68.30 (22.63,187.95)   
Histology subtype
 Serous 64 (64%) 8.8 (6.4,79.8) −3.017 0.002
 Endometrioid 36 (36%) 55.8 (22.85,192.65)   
Lymphatic invasion
 No 41 (41%) 17.7 (7.42,43.47) −3.927 0.000
 Yes 59 (59%) 157.4 (66.43,216.6)   
Distant metastasis
 NO 55 (55%) 13.60 (6.15,46.23) −3.416 0.001
 Yes 45 (45%) 80.90 (29.23,211.03)   
ER
 Positive 70 (70%) 27.90 (8.20,156.30) 0.810 0.418
 Negative 30 (30%) 17.40 (6.90,108.40)   
PR
 Positive 39 (39%) 32.30 (6.85,136.60) 0.265 0.791
 Negative 61 (61%) 27.30 (7.70,136.00)